Page - (000144) - in Biomedical Chemistry: Current Trends and Developments

42(3), 165-174. doi: 10.1016/S0006-3223(96)00312-5 Gold, P. W., Goodwin, F. K., & Chrousos, G. P. (1988a). Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1). New England Journal of Medicine, 319(6), 348-353. doi: 10.1056/NEJM198808113190606 Gold, P. W., Goodwin, F. K., & Chrousos, G. P. (1988b). Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2). New England Journal of Medicine, 319(7), 413-420. doi: 10.1056/NEJM198808183190706 Gold, P. W., Licinio, J., Wong, M. L., & Chrousos, G. P. (1995). Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Annals of the New York Academy of Sciences, 771, 716-729. Gold, P. W., Wong, M. L., Goldstein, D. S., Gold, H. K., Ronsaville, D. S., Esler, M., . . . Kling, M. A. (2005). Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences USA, 102(23), 8303-8308. doi: 10.1073/pnas.0503069102 Habib, K. E., Weld, K. P., Rice, K. C., Pushkas, J., Champoux, M., Listwak, S., Gold, P. W. (2000). Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proceedings of the National Academy of Sciences USA, 97(11), 6079-6084. Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., Howell, C. D. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7(9), 942-947. doi: 10.1038/sj.mp.4001119 Heinrichs, S. C., Lapsansky, J., Lovenberg, T. W., De Souza, E. B., & Chalmers, D. T. (1997). Corticotropin-releasing factor CRF1, but not CRF2, receptors mediate anxiogenic-like behavior. Regulatory Peptides, 71(1), 15-21. Herbert, T. B., & Cohen, S. (1993). Depression and immunity: a meta-analytic review. Psychological Bulletin, 113(3), 472-486. Heuser, I., Bissette, G., Dettling, M., Schweiger, U., Gotthardt, U., Schmider, J., Holsboer, F. (1998). Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depression and Anxiety, 8(2), 71-79. Himmerich, H., Fischer, J., Bauer, K., Kirkby, K. C., Sack, U., & Krugel, U. (2013). Stress-induced cytokine changes in rats. European Cytokine Network, 24(2), 97-103. doi: 10.1684/ecn.2013.0338 Kaestner, F., Hettich, M., Peters, M., Sibrowski, W., Hetzel, G., Ponath, G., Rothermundt, M. (2005). Different activation patterns of proinflammatory cytokines in melancholic and non- melancholic major depression are associated with HPA axis activity. Journal of Affective Disorders, 87(2-3), 305-311. doi: 10.1016/j.jad.2005.03.012 Kessler, R. C., Chiu, W. T., Demler, O., Merikangas, K. R., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry, 62(6), 617-627. doi: 10.1001/archpsyc.62.6.617 Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hughes, M., Eshleman, S., Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry, 51(1), 8-19.